A Phase 4 interventional study of Levetiracetam and Oxcarbazepine in Epilepsy, sponsored by Korea UCB Co., Ltd.. Completed at 23 sites in Korea, Republic of. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-08-20.
Sponsored by Korea UCB Co., Ltd. (part of UCB S.A.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is one of 7 in phase 4, and was the 15th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 353 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 173 across the 18 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Korea UCB Co., Ltd., one of the names counted as UCB S.A.. Under that name alone:
This is the only study on the registry with Korea UCB Co., Ltd. as lead sponsor.
29 studies in Epilepsies, Partial by UCB S.A.: none open now, none under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 29 studies in Epilepsies, Partial by UCB S.A., this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2011, is one of 6 in phase 4, and was the 26th registered.
UCB S.A.’s Epilepsies, Partial studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 29 in Epilepsies, Partial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the long term effectiveness of Levetiracetam (LEV) monotherapy on Treatment Failure Rate in subjects with newly diagnosed partial onset seizures with or without secondary generalized seizures, compared to Oxcarbazepine (OXC) monotherapy over 50 weeks from the first dose
The study duration consists of the following periods:
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
This study's enrollment of 353 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Browse Epilepsies, Partial studies →This is the only study on the registry with Korea UCB Co., Ltd. as lead sponsor.
Compared within Epilepsies, Partial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Levetiracetam twice a day treatment group
Drug: Levetiracetam
Oxcarbazepine twice a day treatment group
Drug: Oxcarbazepine
250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
Percentage of Subjects With a Treatment Failure
Treatment failure is defined as (1) Dropout due to related intolerable adverse event, lack of efficacy or need for addition of another Antiepileptic Drug (AED), or (2) need of a 1-step down-Titration, within 50 weeks from the first dose of study medication.
Time frame: Week 0 (First Dose) to Week 50
Time to the First Seizure Defined as the Time From the First Dose of Medication to the Occurrence of the First Seizure During the 48 Weeks Treatment Period
Time frame: From Week 2 to Week 50 (During Treatment Period )
Percentage of Subjects Who Achieved Seizure Freedom for 24 Consecutive Weeks During the 48 Weeks Treatment Period at Any Time
24-week Seizure Freedom (rate) defined as the number and percentage of subjects who achieved seizure freedom for 24 consecutive weeks during the Treatment Period at any time
Time frame: From Week 2 to Week 50 (During Treatment Period )
Percentage of Subjects Who Achieved Seizure Freedom During the 48 Weeks Treatment Period
48-week Seizure Freedom (rate) defined as the number and percentage of subjects who achieved seizure freedom during the Treatment Period
Time frame: From Week 2 to Week 50 (During Treatment Period )
This study started to enroll subjects in June 2011. A total of 27 investigators enrolled 353 subjects at 23 sites in Korea.
| Milestone | Levetiracetam | Oxcarbazepine |
|---|---|---|
| Started | 175 | 178 |
| Completed | 121 | 122 |
| Not completed | 54 | 56 |
| Withdrew: Protocol violation | 8 | 4 |
| Withdrew: Other reason | 5 | 2 |
| Withdrew: Lack of efficacy | 7 | 2 |
| Withdrew: Ae, non-serious non-fatal | 8 | 17 |
| Withdrew: Sae, non-fatal | 2 | 2 |
| Withdrew: Adverse event, serious fatal | 1 | 1 |
| Withdrew: Withdrawal by subject | 15 | 25 |
| Withdrew: Lost to follow-up | 8 | 3 |
Treatment failure is defined as (1) Dropout due to related intolerable adverse event, lack of efficacy or need for addition of another Antiepileptic Drug (AED), or (2) need of a 1-step down-Titration, within 50 weeks from the first dose of study medication.
| percentage of subjects | Per Protocol Set (LEV Treated Subjects) | Per Protocol Set (OXC Treated Subjects) |
|---|---|---|
| Percentage of Subjects With a Treatment Failure | 12.7 | 23.4 |
| months | Full Analysis Set (LEV Treated Subjects) | Full Analysis Set (OXC Treated Subjects) |
|---|---|---|
| Time to the First Seizure Defined as the Time From the First Dose of Medication to the Occurrence of the First Seizure During the 48 Weeks Treatment Period | 7.556 (NA to NA) | NA (NA to NA) |
24-week Seizure Freedom (rate) defined as the number and percentage of subjects who achieved seizure freedom for 24 consecutive weeks during the Treatment Period at any time
| percentage of subjects | Full Analysis Set (LEV Treated Subjects) | Full Analysis Set (OXC Treated Subjects) |
|---|---|---|
| Percentage of Subjects Who Achieved Seizure Freedom for 24 Consecutive Weeks During the 48 Weeks Treatment Period at Any Time | 53.8 | 58.5 |
48-week Seizure Freedom (rate) defined as the number and percentage of subjects who achieved seizure freedom during the Treatment Period
| percentage of subjects | Full Analysis Set (LEV Treated Subjects) | Full Analysis Set (OXC Treated Subjects) |
|---|---|---|
| Percentage of Subjects Who Achieved Seizure Freedom During the 48 Weeks Treatment Period | 34.7 | 40.9 |
Collected over Adverse Events were collected up to 57 Weeks from Visit 1 (Week -1) to the end of the post-treatment period (down-titration visit, safety follow-up visit).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levetiracetam | — | 15/173 (8.7%) | 67/173 (38.7%) |
| Oxcarbazepine | — | 15/174 (8.6%) | 93/174 (53.4%) |
| Event | Levetiracetam | Oxcarbazepine |
|---|---|---|
| ConvulsionNervous system disorders | 4/173 | 5/174 |
| Cardiac arrestCardiac disorders | 0/173 | 2/174 |
| Abdominal painGastrointestinal disorders | 1/173 | 0/174 |
| DiarrhoeaGastrointestinal disorders | 1/173 | 0/174 |
| Chest discomfortGeneral disorders | 1/173 | 0/174 |
| Fibula fractureInjury, poisoning and procedural complications | 1/173 | 0/174 |
| Thermal burnInjury, poisoning and procedural complications | 1/173 | 0/174 |
| Tibia fractureInjury, poisoning and procedural complications | 1/173 | 0/174 |
| Back painMusculoskeletal and connective tissue disorders | 1/173 | 1/174 |
| Flank painMusculoskeletal and connective tissue disorders | 1/173 | 0/174 |
| Event | Levetiracetam | Oxcarbazepine |
|---|---|---|
| DizzinessNervous system disorders | 25/173 | 50/174 |
| HeadacheNervous system disorders | 25/173 | 36/174 |
| SomnolenceNervous system disorders | 22/173 | 24/174 |
| NasopharyngitisInfections and infestations | 14/173 | 19/174 |
| RashSkin and subcutaneous tissue disorders | 3/173 | 13/174 |
Baseline Characteristics refer to the Randomized Set, consisting of all subjects who were randomized in this study.
| Age, Categorical(Participants) | Levetiracetam | Oxcarbazepine | Total Title |
|---|---|---|---|
| <=18 years | 14 | 13 | 27 |
| Between 18 and 65 years | 145 | 143 | 288 |
| >=65 years | 16 | 22 | 38 |
| Age, Continuous(years) | Levetiracetam | Oxcarbazepine | Total Title |
|---|---|---|---|
| Mean | 39.5 ± 16.7 | 42.7 ± 17.3 | 41.1 ± 17.0 |
| Sex: Female, Male(Participants) | Levetiracetam | Oxcarbazepine | Total Title |
|---|---|---|---|
| Female | 84 | 79 | 163 |
| Male | 91 | 99 | 190 |
| Race (NIH/OMB)(Participants) | Levetiracetam | Oxcarbazepine | Total Title |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 174 | 178 | 352 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 0 | 1 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of Jun 2011, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam